Zi Hao Zhang, Li Chao Yue Sun, Hong Yan Gu, De Chun Jiang, Zhan Miao Yi
{"title":"Associations between <i>SLCO1B1</i>, <i>APOE</i> and <i>CYP2C9</i> and lipid-lowering efficacy and pharmacokinetics of fluvastatin: a meta-analysis.","authors":"Zi Hao Zhang, Li Chao Yue Sun, Hong Yan Gu, De Chun Jiang, Zhan Miao Yi","doi":"10.2217/pgs-2023-0004","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> This meta-analysis was designed to investigate the associations between <i>SLCO1B1</i>, <i>APOE</i> and <i>CYP2C9</i> and the lipid-lowering effects and pharmacokinetics of fluvastatin. <b>Methods:</b> Studies were searched from inception to March 2023, including three SNPs related to fluvastatin, <i>SLCO1B1</i>, <i>CYP2C9</i> and <i>APOE</i>. Weighted mean differences and corresponding 95% CIs were analyzed to evaluate the associations between SNPs and outcomes. <b>Results:</b> <i>SLCO1B1</i> 521T>C was associated with lower total cholesterol and low-density lipoprotein reduction. Patients carrying 521CC or total cholesterol had a significantly higher area under the curve than those carrying 521TT, but no significant difference existed. <b>Conclusion:</b> <i>CYP2C9</i> and <i>SLCO1B1</i> may be associated with the efficacy and pharmacokinetics of fluvastatin.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pgs-2023-0004","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This meta-analysis was designed to investigate the associations between SLCO1B1, APOE and CYP2C9 and the lipid-lowering effects and pharmacokinetics of fluvastatin. Methods: Studies were searched from inception to March 2023, including three SNPs related to fluvastatin, SLCO1B1, CYP2C9 and APOE. Weighted mean differences and corresponding 95% CIs were analyzed to evaluate the associations between SNPs and outcomes. Results:SLCO1B1 521T>C was associated with lower total cholesterol and low-density lipoprotein reduction. Patients carrying 521CC or total cholesterol had a significantly higher area under the curve than those carrying 521TT, but no significant difference existed. Conclusion:CYP2C9 and SLCO1B1 may be associated with the efficacy and pharmacokinetics of fluvastatin.
期刊介绍：
Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field.
Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
